Vicenin-1
(Synonyms: 维采宁 1) 目录号 : GC61786
Vicenin1是从广金钱草的地上部分分离得到的一种糖基黄酮，对血管紧张素转换酶(ACE)有抑制作用，(IC50=52.50μM)。
Cas No.:35927-38-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Vicenin 1 is a C-glycosylflavone isolated from the aerial parts of Desmodium styracifolium, has an inhibitory effect on angiotensin-converting enzyme (ACE)(IC50=52.50 μM)[1].
The target-isolated C-glycosylflavone (Vicenin 1) is evaluated for inhibitory activities. Vicenin 1 embodies effective ACE inhibitory activities with an IC50 value of 52.50 μM. The tested compound 3 (Vicenin 1) shows activity via the generation of chelate complexes within the active center of ACE[1].
[1]. Zhang YQ, et al. Bioassay-guided preparative separation of angiotensin-converting enzyme inhibitory C-flavone glycosides from Desmodium styracifolium by recycling complexation high-speed counter-current chromatography. J Pharm Biomed Anal. 2015 Jan;102:276-81.
| Cas No. | 35927-38-9 | SDF | |
| 别名 | 维采宁 1 | ||
| Canonical SMILES | OC1=C([C@H]2[C@@H]([C@H]([C@H](O)CO2)O)O)C(O)=C(C(C=C(C3=CC=C(O)C=C3)O4)=O)C4=C1[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)CO | ||
| 分子式 | C26H28O14 | 分子量 | 564.49 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7715 mL | 8.8576 mL | 17.7151 mL |
| 5 mM | 0.3543 mL | 1.7715 mL | 3.543 mL |
| 10 mM | 0.1772 mL | 0.8858 mL | 1.7715 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Acute and repeated doses (28 days) oral toxicity study of Vicenin-1, a flavonoid glycoside isolated from fenugreek seeds in laboratory mice
Regul Toxicol Pharmacol 2016 Nov;81:522-531.PMID:27773753DOI:10.1016/j.yrtph.2016.10.013.
Vicenin-1 (fenugreek glycoside) has been proven to possess potent anti-inflammatory and anti-oxidant activity. The objective of the present investigation was to determine in-vivo acute and subacute (28-days repeated dose) oral toxicity of Vicenin-1 isolated from fenugreek seed. Vicenin-1 (93%) was isolated from a hydroalcoholic extract of fenugreek seed and characterized using HPLC, TLC, 1H NMR and 13C NMR. Acute oral toxicity (AOT) and subacute toxicity studies of Vicenin-1 were carried out according to OECD 425 (up-and-down procedure) and OCED 407 guidelines in Swiss albino mice. In AOT, Vicenin-1 showed 10% mortality when administered at a dose of 5000 mg/kg. However, when Vicenin-1 was administered for at doses of 37.5, 75, or 150 mg/kg 28-days it did not show any mortality at the administered doses. Vicenin-1 (75 mg/kg) did not show observational, behavioral, biochemical or histopathological toxic effects. There were minor alterations in body weight, hematology, and histopathology of mice administered with Vicenin-1 (150 mg/kg), but these changes were within normal laboratory ranges. The highest concentration of Venicin-1 was found in liver (3.46%) followed by lung (0.65%). In conclusion, Vicenin-1 showed median lethal dose (LD50) of 4837.5 mg/kg with no-observed-adverse-effect levels (NOAEL) at 75 mg/kg and lowest adverse effect levels (LOAEL) at 150 mg/kg for both sexes of mice during AOT and sub-acute toxicity study, respectively.
Development and validation of HPLC method for Vicenin-1 isolated from fenugreek seeds in rat plasma: application to pharmacokinetic, tissue distribution and excretion studies
Pharm Biol 2016 Nov;54(11):2575-2583.PMID:27181500DOI:10.3109/13880209.2016.1172245.
Context: Vicenin-1, a flavonol glycoside, has potent platelet aggregation inhibition, antioxidant, radioprotectants and anti-inflammatory activities. Objective: To establish a rapid, simple, precise and sensitive high-performance liquid chromatography (HPLC) method for determination of Vicenin-1 in rat plasma, and to investigate the pharmacokinetics, tissue distribution and excretion after a single 60 mg/kg oral dose in rats. Materials and methods: Vicenin-1 was extracted by solid-liquid extraction through Tulsicon® ADS-400 (0.40-1.2 mm). Chromatographic separation was achieved by HPLC with a C18 column with a mobile phase composed of water and acetonitrile (75:25 v/v) and a flow rate of 1 mL/min along with UV detection at 210 nm. Results: Good linearity of calibration curve was found between 10.5 and 100.5 μg/mL (R2 =0.995) for plasma and tissue, whereas 2.5-500 μg/mL (R2 =0.999) for the urine and stool samples. The extraction recoveries were 98.51-99.58% for Vicenin-1 in plasma, whereas intra-day and inter-day precision were validated by relative standard deviation (%RSD), that came in the ranges of 1.16-1.79% and 1.28-1.73%, respectively. The pharmacokinetics results showed Cmax (7.039 μg/mL) and Tmax (2 h) after oral administration of Vicenin-1. Tissue distribution study showed that the highest concentration of Vicenin-1 was achieved in the liver followed by the lung. Approximately 24.2% of its administered dose was excreted via urinary excretion route. Conclusion: The first-pass metabolism, poor solubility and presence of reducing sugar moiety in Vicenin-1 may decrease its bioavailability. The developed method is sensitive, specific and was successfully applied to the pharmacokinetics, tissue distribution and excretion studies of Vicenin-1 in rats.
Synthesis of Vicenin-1 and 3, 6,8- and 8,6-di-C-beta-D-(glucopyranosyl-xylopyranosyl)-4',5,7-trihydroxyflavones using two direct C-glycosylations of naringenin and phloroacetophenone with unprotected D-glucose and D-xylose in aqueous solution as the key reactions
Carbohydr Res 2010 Sep 3;345(13):1825-30.PMID:20605015DOI:10.1016/j.carres.2010.04.001.
Vicenin-3 was synthesized from naringenin via a short five-step reaction, which included two regioselective direct C-glycosylations with d-glucose and d-xylose (yields: 22% and 30%, respectively) as the key reactions for a total yield of 4.4%. Vicenin-1 was also synthesized from phloroacetophenone via a 10-step reaction, including the same glycosylation described above, for a total yield of 2.7% with a vicenin-3 yield of 1.7%.